Insider Purchases: Inside the Buy
Tag: Biotech Humor
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?